Zacks Bull and Bear of the Day Highlights: Cincinnati Financial, ArcelorMittal, Biogen, Sanofi and Osiris Therapeutics

       Zacks Bull and Bear of the Day Highlights: Cincinnati Financial,
            ArcelorMittal, Biogen, Sanofi and Osiris Therapeutics

PR Newswire

CHICAGO, March 14, 2013

CHICAGO, March 14, 2013 /PRNewswire/ -- Zacks Equity Research highlights
Cincinnati Financial (Nasdaq:CINF) as the Bull of the Day and ArcelorMittal
(NYSE:MT) as the Bear of the Day. In addition, Zacks Equity Research provides
analysis on Biogen Idec (Nasdaq:BIIB), Sanofi (NYSE:SNY) and Osiris
Therapeutics (Nasdaq:OSIR).


Full analysis of all these stocks is available at

Here is a synopsis of all five stocks:

Bull of the Day:

This S&P 500 dividend aristocrat—with a juicy dividend yield of 3.5%--has been
increasing its dividends for the last 52 years in a row—a record matched by
only nine US public companies.

Further, Cincinnati Financial (Nasdaq:CINF), a Zacks Rank # 1 (Strong Buy)
stock has been benefitting from an above industry average premium growth,
expansion in underwriting margins and excellent performance of its diversified
investment portfolio.

And those are not the only reasons to buy this stock.

Cincinnati Financial, headquartered in Fairfield, OH, is one of the top 25
property and casualty insurers in the US. The company operates through the
Cincinnati Insurance Company, which itself has four insurance subsidiaries,and
through two financial services subsidiaries.

The company, which was started by independent insurance agents, has an
agent-centered business model. The company believes that independent agency
system is its core strength and most important competitive advantage.

Bear of the Day:

Global steel is going through challenging times. Demand is down sharply in
China and Europe. Intense competition and overcapacity has led to a steep
decline in prices.

Further, ArcelorMittal (NYSE:MT) — the world's largest steelmaker is greatly
exposed to economic woes in Europe.

Given weak fundamentals for the industry and the Europe exposure, the outlook
for this steel giant remains cloudy at present.

ArcelorMittal is world's leading steel and mining company with 130 million
tons of annual production capacity and 245,000 employees across 60 countries.

The company reported a net loss of $4 billion or $2.58 per share for the
fourth quarter of 2012 compared with a net loss of $1 billion or $0.65 per
share for the prior-year quarter.

Latest Posts on the Zacks Analyst Blog:

Biogen Files Hemophilia B Application

Biogen Idec (Nasdaq:BIIB) recently announced the submission of a Biologics
License Application (BLA) for its recombinant factor VIII Fc fusion protein
(rFVIIIFc). The company is seeking US Food and Drug Administration (FDA)
approval for rFVIIIFc for the treatment of hemophilia A.

The regulatory filing was based on results from the A-LONG study. FDA approval
for rFVIIIFc would represent the first significant advancement in hemophilia A
treatment in more than two decades.

We note that Biogen's hemophilia B candidate, rFIXFc, is currently under FDA
review. With the FDA granting standard review, a response from the agency
regarding the approval status of rFIXFc should be out in the fourth quarter of
this year.

A convenient dosing schedule (supported by a longer duration of action and a
suitable safety profile) could help rFIXFc and rFVIIIFc capture share from
existing products in the hemophilia market.

Upcoming Catalysts

Meanwhile, Biogen has some other significant pipeline catalysts coming up, the
most important being an update on the regulatory status of Tecfidera (BG-12).
Tecfidera, Biogen's oral multiple sclerosis candidate, is currently under
review in both the US and the EU. A response in the US should be out this
month. We believe Tecfidera could become a leader in the oral multiple
sclerosis market once launched.

Biogen currently carries a Zacks Rank #3 (Hold). Key products, Avonex and
Tysabri, should continue contributing significantly to sales. Tecfidera, if
approved, should help drive long-term growth. However, we expect competition
in the multiple sclerosis market to increase with the entry of Sanofi's
(NYSE:SNY) Aubagio.

Companies that currently look interesting include Osiris Therapeutics
(Nasdaq:OSIR), a Zacks Rank #1 (Strong Buy) stock.

Get the full analysis of all these stocks by going to

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are
likely to outperform (Bull) or underperform (Bear) the markets over the next
3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from
Zacks Equity Research about the latest news and events impacting stocks and
the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous analyst coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them keen
insights to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today by visiting

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In
short, it's your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance
numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.